- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07946627
Everolimus Post-Bland Hepatic Artery Embolization in Patients With Neuroendocrine Tumors (NETs) With Liver Metastasis
Phase 2 Dose Optimization Trial of Everolimus Post-Bland Hepatic Artery Embolization (Evero-Embo) in Patients With Neuroendocrine Tumors (NETs) With Liver Metastasis
This study is being done to learn whether people with neuroendocrine tumors (NETs) that have spread to the liver can safely tolerate a lower dose of everolimus after bland hepatic artery embolization (HAE).
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 2
Contactos e Locais
Contato de estudo
- Nome: Lowell B Anthony, MD
- Número de telefone: 859-257-4488
- E-mail: lan225@uky.edu
Locais de estudo
-
-
Kentucky
-
Lexington, Kentucky, Estados Unidos, 40536
- University of Kentucky
-
Contato:
- Lowell B Anthony, MD
- Número de telefone: 859-257-4488
- E-mail: lan225@uky.edu
-
Investigador principal:
- Lowell B Anthony, MD
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Patients must have histologically or cytologically confirmed Grade 1 or 2 NET with measurable liver metastasis (≥1.0 cm).
- Morphologically progressive disease by RECIST 1.1 and/or ≥25% but ≤75% tumor burden in the liver.
- Prior tolerance of at least 5 mg daily everolimus for ≥5 days pre-HAE. NOTE: There is no maximum amount of time a patient may be taking Everolimus before HAE as the study focuses on after the pre-HAE dose is established.
- Prior therapy: Patients are eligible regardless of the number or type of prior therapies and without a requirement to have received a specific therapy prior to enrollment. Patients will take everolimus leading up to the embolization once enrolled in the study. They will only be enrolled in the study for their first hepatic artery embolization. They must be 30 days out since their last cancer treatment of any kind, not including somatostatin analogs.
- Age ≥18 years.
- ECOG performance status ≤2 (see Appendix A).
- Patients must have adequate organ and marrow function as defined below:
- absolute neutrophil count ≥1,000/mcL
- platelets ≥100,000/mcL
- total bilirubin ≤ institutional upper limit of normal (ULN)
- Child-Turcotte-Pugh class A; B dose reduction is recommended at 5mg QD or less; C recommend non-usage of everolimus
- Creatinine (or GFR) ≤ institutional ULN (Appendix B)
- GFR, glomerular filtration rate (or creatinine) There are no dose reductions required for patients in any stage of renal failure for everolimus
- Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial.
- For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.
- Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.
- Patients with a prior malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.
- Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better.
- Ability to understand and the willingness to sign a written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of study participants.
Exclusion Criteria:
- Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > Grade 1) with the exception of alopecia.
- Prior transhepatic artery embolization.
- Contraindication to arteriography or embolization.
- Prior chemotherapy or peptide receptor radionuclide therapy within 1 month.
- Biliary stent or choledocho-enteric anastomosis.
- Patients who are receiving any other investigational agents for the treatment of this cancer.
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to everolimus
- Concomitant medications: Patients should only be excluded from trial participation when clinically relevant known or predicted drug-drug interactions or potential overlapping toxicities will impact safety or efficacy. Drug-drug interactions of risk level X will be excluded from the trial unless an alternative medication can be substituted. Drug-drug interactions are classified into classes A, B, C, D and X. A Class X drug interaction represents a high-risk, contraindicated combination where the risks of taking the medications together clearly outweigh any potential benefits. These medications include Antihepaciviral Combination Products, BCG Products, Brivudine, Chikungunya Vaccine (Live), Chloramphenicol (Systemic), Cladribine, Dengue Tetravalent Vaccine (Live), Etrasimod, Fexinidazole, Grapefruit Juice, Inhibitors of CYP3A4 (Strong) and P-glycoprotein, Mumps- Rubella- or Varicella-Containing Live Vaccines, Nadofaragene Firadenovec, Natalizumab, Pimecrolimus, Pimozide, Poliovirus Vaccines (Live/Oral), Tacrolimus (Topical), Talimogene Laherparepvec, Tertomotide, Thiamphenicol, Typhoid Vaccine, Vaccines (Live), Yellow Fever Vaccine, Zoster Vaccine (Live/Attenuated). Additionally, patients should avoid taking everolimus while on strong CYP3A4 inhibitors. They should have everolimus dose reduction to 2.5 mg PO while on moderate CYP34A inhibitors and/or PgP inhibitors. An increase in everolimus dose is recommended when co-administered with a strong CYP3A4 inducer (see package insert, Appendix C).
- Patients with uncontrolled intercurrent illness.
- Pregnant women are excluded from this study because everolimus is an mTOR inhibitor agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with everolimus, breastfeeding should be discontinued if the mother is treated with everolimus. NOTE: Patients treated with everolimus should use highly effective birth control during treatment and for 8 weeks after their last everolimus dosing. Male patients with female partners of reproductive potential should be advised to use effective contraception during treatment with everolimus and for 4 weeks after the last dose
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Everolimus following Bland Hepatic Artery Embolization
Everolimus 5mg will be provided orally for 7 days pre embolization then every other day beginning day 2 through day 30, post embolization. Bland Hepatic Artery procedure will occur on Day 0. |
Everolimus 5mg will be provided orally for 7 days pre embolization then every other day beginning day 2 through day 30, post embolization Bland Hepatic Artery Embolization (HAE) will occur on Day 0. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Percentage of patients who can tolerate everolimus pre and post HAE
Prazo: Pre-study to Day 30
|
To assess the percentage of patients who can tolerate ½ pre-embolization everolimus dose administered every other day post-bland hepatic artery embolization of liver metastasis in neuroendocrine tumor (NET) patients (dose optimization trial). |
Pre-study to Day 30
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Objective Response Rate
Prazo: Pre-study to Day 30
|
To determine the objective response rate (ORR) and hepatic progression-free survival (hPFS). |
Pre-study to Day 30
|
|
Progression Free Survival
Prazo: Pre-study to Day 30
|
To determine the objective response rate (ORR) and hepatic progression-free survival |
Pre-study to Day 30
|
|
Biochemical Response
Prazo: Pre-study to Day 30
|
To evaluate biochemical response using Chromogranin A (CGA), serotonin, and 5-HIAA levels, defined as a 50% reduction from baseline if elevated. |
Pre-study to Day 30
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Lowell B Anthony, MD, University of Kentucky
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 120321
- MCC-26-GI-150 (Outro identificador: University of Kentucky)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .